Japanese Biotechs Promote “Relationship Building” In Developing Marketing Deals
This article was originally published in The Pink Sheet Daily
Executive Summary
Eisai and Astellas execs tell BIO attendees that forming strong initial partnerships provides a basis for expanding alliances into new products and geographies.
You may also be interested in...
Eisai Enters Biologics Arena With $325 Million Morphotek Acquisition
Japanese firm plans to grow U.S. sales to $4 billion via expanded sales force of 1,500 by 2011, Eisai tells “The Pink Sheet” DAILY.
Astellas VP-Business Development Masaki Doi: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
Japanese pharma exec discusses Astellas’ global licensing strategy, the FibroGen deal, and the changing paradigm of Japanese deal flow.
Japanese Mergers Provide Opening For Biotech Deals – Novartis Licensing Head
But multinationals may be increasingly squeezed out of Japanese deals due to the merger wave, company exec tells BIO-Asia conference in Tokyo.